Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 7 Overview of the methodological processes for

Published byMathieu Malenfant Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 7 Overview of the methodological processes for"— Presentation transcript:

1 Figure 7 Overview of the methodological processes for
RLHC and how the radiomics workflow fits into the development of a CDSS Figure 7 | Overview of the methodological processes for RLHC and how the radiomics workflow fits into the development of a CDSS. Data selection, discovery, collection and preparation, model(s) development/validation and implementation, assessment of clinical utility and ultimately refinement through continuous repetition of the process (quality control and assurance protocols are requisite throughout the process). Lambin, P. et al. (2017) Radiomics: the bridge between medical imaging and personalized medicine Nat. Rev. Clin. Oncol. doi: /nrclinonc

Download ppt "Figure 7 Overview of the methodological processes for"

Similar presentations

Figure 1 Estimated annual percentages of new

Figure 1 Estimated annual percentages of new
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Figure 3 Response after appearance of a new lesion

Figure 3 Response after appearance of a new lesion
Figure 2 The US Centers for Disease Control and

Figure 2 The US Centers for Disease Control and
Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer
Figure 1 Concept of the therapeutic index

Figure 1 Concept of the therapeutic index
Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.
Figure 2 Multiscale modelling in oncology

Figure 2 Multiscale modelling in oncology
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Generations of cancer vaccine antigens

Figure 1 Generations of cancer vaccine antigens
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Three-step approach to the assessment and management

Figure 2 Three-step approach to the assessment and management
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Copy-number variations in multiple myeloma

Figure 2 Copy-number variations in multiple myeloma

Similar presentations

Ads by Google